Comparative Pharmacology
Head-to-head clinical analysis: FOLEX versus IDVYNSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLEX versus IDVYNSO.
FOLEX vs IDVYNSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
None Documented
None Documented
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent